Brighton Jones LLC Seagen Inc. Transaction History

Brighton Jones LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	BUY	$191.51 - $216.16 $57,836 - $65,280	302 Added 27.55%	1,398 $296,000
Q2 2023 Jul 31, 2023	SELL	$187.64 - $206.25 $67,362 - $74,043	-359 Reduced 24.67%	1,096 $210,000
Q1 2023 May 08, 2023	BUY	$127.59 - $203.08 $185,643 - $295,481	1,455 New	1,455 $294,000
Q3 2022 Nov 09, 2022	BUY	$135.27 - $180.11 $405 - $540	3 Added 0.17%	1,809 $248,000
Q2 2022 Aug 04, 2022	SELL	$108.81 - $179.33 $870 - $1,434	-8 Reduced 0.44%	1,806 $320,000

Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $1,794 - $2,367	-15 Reduced 0.82%	1,814 $262,000
Q4 2021 Feb 03, 2022	BUY	$142.57 - $190.86 $4,989 - $6,680	35 Added 1.95%	1,829 $283,000
Q3 2021 Nov 04, 2021	SELL	$142.45 - $169.82 $209,686 - $249,975	-1,472 Reduced 45.07%	1,794 $305,000
Q2 2021 Aug 10, 2021	BUY	$135.08 - $161.1 $210,319 - $250,832	1,557 Added 91.11%	3,266 $516,000
Q1 2021 May 07, 2021	SELL	$137.51 - $190.8 $962 - $1,335	-7 Reduced 0.41%	1,709 $237,000
Q4 2020 Feb 10, 2021	BUY	$164.63 - $211.93 $282,505 - $363,671	1,716 New	1,716 $301,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Brighton Jones LLC, based on Form 13F filings with the SEC.

Stay updated on Brighton Jones LLC with notifications on news.